nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab', 'pancreatic']
nimotuzumab, an egfr inhibitor, when added to gemcitabine has shown promise with an increase in os in small subgroup of patients with kras wild-type advanced pancreatic cancer. #asco22 
MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.